Vobramitamab duocarmazine: &quot;Vobra duo yields antitumor activity in mCRPC as demonstrated by ORR, PSA response rate, and 6-month rPFS rate“; Prostate cancer

vobramitamab duocarmazine (MGC018) - MacroGenics

Sep 17, 2024